Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus.pdf.pdf

Can J Diabetes 39 (2015) 4e9
Contents lists available at ScienceDirect
Canadian Journal of Diabetes
journal homepage:

Practical Diabetes
Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1
and Type 2 Diabetes Mellitus
Lori Berard RN, CDE a,*, Gail eill BNSc, RN, MEd, CDE b
a Winnipeg Regional Health Authority, Health Sciences Centre, Winnipeg, Manitoba, Canada
b Mount Sinai Hospital, Toronto, Ontario, Canada
article info abstract
Article history: Here, we discuss certain practical issues related to use of insulin degludec, a new long-acting basal insulin
Received 3 December 2013 analogue. Degludec provides uniform (“peakless”) action that extends over more than 24 hours and is highly
Received in revised form consistent from dose to dose. Like the 2 previously available basal analogues (detemir and glargine), degludec is
3 February 2014
expected to simplify dose adjustment and enable patients to reach their glycemic targets with reduced risk of
Accepted 13 February 2014
hypoglycemia. Phase 3 clinical trials involving type 1 and type 2 diabetes have demonstrated that degludec was
noninferior to glargine in allowing patients to reach a target glycated hemoglobin (A1C) of 7%, and nocturnal
Keywords:
hypoglycemia occurred significantly less frequently with degludec. In addition, when dosing intervals vary
basal insulin
degludec substan